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Abstract
Background: The purpose of this study was to investigate the potential of antibody-directed immunotherapy
targeting the aminophospholipid phosphatidylserine, which promotes immunosuppression when exposed in the
tumor microenvironment, alone and in combination with antibody treatment towards the T-cell checkpoint
inhibitor PD-1 in breast carcinomas, including triple-negative breast cancers.
Methods: Immune-competent mice bearing syngeneic EMT-6 or E0771 tumors were subjected to treatments
comprising of a phosphatidylserine-targeting and an anti-PD-1 antibody either as single or combinational treatments.
Anti-tumor effects were determined by tumor growth inhibition and changes in overall survival accompanying each
treatment. The generation of a tumor-specific immune response in animals undergoing complete tumor regression
was assessed by secondary tumor cell challenge and splenocyte-produced IFNγ in the presence or absence of irradiated
tumor cells. Changes in the presence of tumor-infiltrating lymphocytes were assessed by flow cytometry, while
mRNA-based immune profiling was determined using NanoString PanCancer Immune Profiling Panel analysis.
Results: Treatment by a phosphatidylserine-targeting antibody inhibits in-vivo growth and significantly enhances the
anti-tumor activity of antibody-mediated PD-1 therapy, including providing a distinct survival advantage over
treatment by either single agent. Animals in which complete tumor regression occurred with combination treatments
were resistant to secondary tumor challenge and presented heightened expression levels of splenocyte-produced IFNγ.
Combinational treatment by a phosphatidylserine-targeting antibody with anti-PD-1 therapy increased the number of
tumor-infiltrating lymphocytes more than that observed with single-arm therapies. Finally, immunoprofiling analysis
revealed that the combination of anti-phosphatidylserine targeting antibody and anti-PD-1 therapy enhanced
tumor-infiltrating lymphocytes, and increased expression of pro-immunosurveillance-associated cytokines while
significantly decreasing expression of pro-tumorigenic cytokines that were induced by single anti-PD-1 therapy.
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Conclusions: Our data suggest that antibody therapy targeting phosphatidylserine-associated immunosuppression,
which has activity as a single agent, can significantly enhance immunotherapies targeting the PD-1 pathway in murine
breast neoplasms, including triple-negative breast cancers.
Keywords: Phosphatidylserine, Checkpoint inhibitor, Combination immunotherapy, Breast cancer, Triple-negative
breast cancer
Background
In the United States alone over 200,000 women will be di-
agnosed with breast cancer (BC) this year, with greater
than 50,000 succumbing to their disease [1]. Treatment
options for those diagnosed with BC are complicated by
the highly heterogeneous nature of the disease. Depending
upon the subtype of BC, the majority of patients receive
surgery combined with radiotherapy, hormonal therapy,
or chemotherapy, and if caught early the prognosis is typ-
ically favorable [2, 3]. In addition to the use of systemic
treatments, targeted therapies have succeeded in extend-
ing patient survival in some subtypes of BC, most notably
those directed against the ERBB2 receptor [4–6]. Unfortu-
nately for the treatment of triple-negative breast cancer
(TNBC), one of the most aggressive subtypes of BC, no
targeted therapies have shown clinical efficacy to date [7].
TNBC develops earlier in life, being frequently diagnosed
in premenopausal women. TNBC patients receive surgery
and chemotherapy, yet have higher relapse rates, shorter
progression-free survival, and reduced overall survival
than observed in other types of BC, thus underlining the
need for better therapeutic treatments [8, 9].
It is now recognized that cytotoxic chemotherapeutics,
such as those used to treat TNBC, can inadvertently pro-
mote an immunosuppressive tumor microenvironment
through changes in the subcellular localization of the
immune checkpoint regulator phosphatidylserine (PS) [10–
12]. PS normally resides in the inner plasma membrane
leaflet in normal mammalian cells. Environmental condi-
tions arise in tumors that cause cellular stress, such as
oxygen radicals, hypoxia, or anti-cancer treatments includ-
ing irradiation and chemotherapy, causing PS in tumor-
associated vascular endothelial cells and tumor cells to
undergo subcellular relocalization to the outer plasma
membrane with subsequent exposure to the extracellular
environment [13, 14]. This relocalization in tumors pro-
motes PS recognition and pathway activation in local
immune-modulating cells that regulate both the innate and
adaptive immune responses [15]. On myeloid and lymphoid
cells, the TAM and TIM families of receptors recognize
and bind to PS, resulting in the release of immune-
suppressive cytokines, inhibition of inflammatory
signaling pathways, and the attenuation of innate and
adaptive cellular responses [15–19]. This may be espe-
cially pertinent for the development and expansion of
CD8+ T cells since TIM-3, which functions as a negative
regulator of TCR activation and development of a T-
helper (Th) type 1 responses, binds to PS [15, 20, 21]. In
addition, PS exposure in the tumor microenvironment
also negatively impacts the antigen-presentation function
of dendritic cells in part through downregulating MHC II
function and expression [22]. Upon binding to and ingest-
ing PS-expressing cells, dendritic cells are prevented from
progressing into a mature phenotype, and are incapable of
properly processing and presenting essential costimulatory
molecules required for functional antigen presentation to
T cells [10, 14]. Inhibition of both innate and adaptive re-
sponses by PS exposure contributes to the initiation and
maintenance of an immunosuppressive microenviron-
ment, which in turn promotes tumor progression and
metastatic disease by subjugating the host’s ability to
recognize and eliminate abnormal cells [23, 24].
Because of the ability of PS exposure in the tumor
microenvironment to promote tumor progression, thera-
peutic modalities blocking the binding of PS to specific
receptors on immune cells is recognized as a potential
target for cancer therapy [22, 25]. In fact bavituximab, a
PS-targeting antibody, is undergoing clinical evaluation
for the treatment of solid tumors with encouraging results
[26–28]. Studies in rodent models with PS-targeting anti-
bodies (including mch1N11) demonstrate localization to
tumor-specific PS-expressing cells and the capability to elicit
an anti-tumor immune response, particularly when com-
bined with chemotherapy or radiotherapy [12, 14, 22, 29].
While these results are encouraging, it remains to be
determined in which therapeutic regimen PS-targeting
antibodies will ultimately have the greatest impact on im-
proving patient outcome: as a single agent, in conjunction
with chemotherapy; or used in combination with other
immunotherapies such as those targeting the checkpoint
inhibitor programmed death 1 (PD-1).
The programmed death 1 (PD-1) receptor and its li-
gands 1 and 2 (PD-L1/L2) are key regulators in control-
ling the ability of tumors to downregulate the adaptive
immune response and disrupt T-cell checkpoint pathways
[30, 31]. PD-1 is expressed on T cells, B cells, natural killer
cells, dendritic cells, and many tumor-infiltrating lympho-
cytes (TILs) [32]. The PD-1 ligands, PD-L1 and PD-L2, are
also expressed in resting immune system cells, including T
cells, B cells, and natural killer cells. In normal tissues, the
Gray et al. Breast Cancer Research  (2016) 18:50 Page 2 of 14
PD-1:PD-L1/L2 interactions are critical inhibitory regula-
tors that act to protect against tissue damage by limiting in-
flammatory reactions mediated by T cells and other
immune system components during infections [32]. In can-
cers, tumor cell expression of PD-L1 is capable of interact-
ing with PD-1 on cells in the tumor microenvironment,
where it serves to inhibit both effector T-cell activation and
cytolytic responses to tumor cells [30, 33–35]. Clinical trials
using antibodies to inhibit PD-1/PD-L1 activity have shown
efficacy in patients with nonsmall-cell lung cancer, melan-
oma, and kidney cancers [36, 37]. While further evaluation
is necessary, data suggest that levels of PD-1 expression in
patients’ tumors may predict response rates [38–40]. Cur-
rently, it is not known whether anti-PD-1/PD-L1 therapies
will have efficacy in BCs. However, it has been demonstrated
in three independent studies that upwards of 20–50 % of all
BC patients, including those diagnosed with TNBC, have
detectable PD-L1 levels in tumor biopsies [41–43].
Because of the ability of both PS and PD-1 to contribute
to an immunosuppressive tumor microenvironment, we
sought to determine whether blocking recognition of PS
and PD-1 alone and in combination are effective therapies
in BC models, including TNBC. Our data show that com-
bining the PS-targeting antibody mch1N11 with anti-PD-1
antibody therapy has significantly greater inhibitory tumor
growth activity and significantly increased overall survival
compared with either single treatment alone, and is cap-
able of causing complete tumor regression. In addition,
mice that received combinational treatment and experi-
enced complete tumor regression had increased splenic
IFNγ production, and were capable of mounting a durable
immune response that negated the growth of these TNBC
cells when rechallenged. Analysis of tumors by flow cy-
tometry showed that the combined treatment increases
intratumoral TIL levels more than observed with either
single treatment. Further immunoprofiling analysis dem-
onstrated that while combinational therapy was capable of
increasing the expression of pro-immune activating cell
types and cytokines over that observed in single-arm treat-
ment groups, the addition of a PS targeting antibody to
anti-PD-1 therapy also has the ability to downregulate crit-
ical pro-tumorigenic cytokines, including IL-4, IL-9, and
IL-17, which were induced by anti-PD-1 treatment [44–
46]. These data demonstrate that antibody-mediated
blockade of PS-mediated immunosuppression enhances
the anti-tumor effects of PD-1 targeted therapy by further
augmenting immune activation while simultaneously at-
tenuating negative pro-tumorigenic secondary responses
that accompany targeting PD-1 in TNBC.
Methods
Cell lines
The murine TNBC cancer line E0771 was purchased from
CH3 BioSystems, LLC (Buffalo, NY, USA). EMT-6 was
obtained from ATCC (Manassas, VA, USA). All cells were
maintained in RPMI-1640 (GIBCO) supplements with
10 % v/v heat-inactivated fetal bovine serum (GIBCO,
Waltham, MA, USA).
Antibodies
PS-targeting antibody chimeric mch1N11 is a mouse
IgG2a-kappa with human variable heavy and light chain
regions; C44 is an IgG2a isotype. Purified anti-mouse
PD-1 (clone RMP1-14) was obtained from BioXcell
(West Lebanon, NH, USA). All in-vivo antibodies tested
negative for endotoxin with a limit of detection of 0.5
EU/ml of stock antibody. Antibodies for flow cyt-
ometer analysis were CD45 (clone 30-F11), CD3e
(clone 17A2), CD4 (clone GK1.5), CD8a (clone 53–
6.7), and CD25 (clone PC61.5), all obtained from Bio-
science (San Diego, CA, USA). Antibodies for immu-
nohistochemistry were anti-PD-L1 antibody (clone
MIH6, catalog number ab80276; Abcam, Cambridge,
MA, USA) and anti-PD-1 antibody (clone RMP1-14,
catalog number ab63477; Abcam).
Immunohistochemistry
E0771 and EMT-6 tumors were imbedded in OCT
medium and frozen in a dry-ice isopentane bath.
Tissue sections were cut (5 μm) and stained for PD-
L1 and PD-1 positive cells. Tissue samples were
stained with secondary antibodies labeled with perox-
idase or alkaline phosphatase followed by counterstain
with hematoxylin and analyzed by bright-field micros-
copy. Slides were digitized using a Lumenera infinity
digital camera and version 6.4 software (Lumenera,
ON, Canada).
Animals
Female C57BL/6 or Balb/c mice 4–6 weeks old were
purchased from Charles River Laboratories (Wilmington,
MA, USA). All studies were approved by the Institutional
Animal Care and Use Committee at the University of
California, Irvine, USA.
In-vivo studies
EMT-6/E0771 tumor cells were suspended at 1 × 107/ml in
Matrigel (50 % v/v) in PBS and 0.1 ml was injected into the
9/10 mammary fat pad (E0771, C57BL/6; EMT-6, Balb/c).
Tumor volumes (V) were calculated using the formula:
V ¼ LW  Hð Þ  0:5
where L is the length, W is the width, and H is the
height of the tumor. The percent tumor growth inhib-
ition (% TGI) was calculated using the formula:
% TGI ¼ 1 – T=Cð Þ  100
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where T is the mean tumor volume of the treated group
at the end of study and C is the mean tumor volume of the
control group at the end of study. For tumor rechallenge
studies, animals with no palpable tumor were injected with
E0771 cells under the same initial dosing conditions but
on the opposing mammary fat pad (4/5). The tumor re-
challenge response endpoint was expressed as tumor
growth delay and the difference in time (days) was calcu-
lated between the growth delay of the treated group and
the naïve control group. All treatment was administered
via intraperitoneal injection in 100 μl volumes twice weekly
(C44 control, 10 mpk; mch1N11, 10 mpk; anti-PD-1 2.5
mpk; and mch1N11 + anti-PD-1, 10/2.5 mpk respectively).
Doses were selected though preliminary maximum toler-
ated dose (MTD) studies (data not presented), and no
toxicity/weight loss was encountered in the data presented.
IFNγ EliSpot
Spleens were obtained from naïve nontumor-bearing mice
that were untreated, single, or combination treated, or
from E0771 tumor-bearing mice treated with C44, or from
animals with regressed E0771 tumors following treatment
with mch1N11 and anti-PD-1. Spleens were harvested on
day 12 following tumor implantation or from nontumor
animals following a matching treatment regimen. Single-
cell preparations of splenocytes were resuspended in
RPM1-1640 supplemented with 10 % FCS containing anti-
biotics at 1 × 106 cells/ml and 100 μl added, in triplicate,
to wells of EliSpot microplates coated with anti-mouse
IFNγ IgG, in the absence or presence of 1 × 105 irradiated
(15,000 rad) E0771 cells to determine tumor-specific
stimulation. Plates were incubated for 48 h at 37 °C and
spots were developed using anti-mouse IFNγ IgG–HRP
conjugate followed by peroxidase substrate. Spots were
counted using an automated EliSpot plate reader.
Flow cytometry
Tumors were excised from mice and physically dissociated
and digested in 1 mg/ml collagenase (Sigma, St. Louis, MO,
USA), 0.1 mg/ml hyaluronidase (Sigma, St. Louis, MO,
USA), and 200 units/ml DNase type IV (Sigma, St. Louis,
MO, USA) for 1.5 h at 37 °C and passed through a 70 μm
sieve filter (Falcon, Corning, NY, USA). Cells were col-
lected, treated with ACK lysis buffer to remove red blood
cells, washed twice with PBS, resuspended in FACS staining
buffer, and stained with antibodies for 20 min at 4 °C.
NanoString immunoprofiling analysis
E0771 RNA was prepared from six tumors for each treat-
ment group shown in Fig. 2a at study end (day 26) by
Direct-zol™ RNA mini prep kit (ZymoResearch, Irvine,
CA, USA). Gene expression was directly measured via
counts of corresponding mRNA in each sample using an
nCounter (NanoString, Seattle, WA, USA) GX murine
PanCancer Immune Profiling Panel, which is a multiplex
assay for 770 genes involved in the murine inflammatory
response [47]. The nCounter system allows for direct
detection and counting of nucleic acid via reporter probes
appended with multiple fluorophore barcodes and bio-
tinylated capture probes that attach to microscopic beads,
which are then affixed to lanes in a translucent cartridge
and read in an optical scanner. Batches of 12 separate
samples (six from each treatment group) at one time were
prepared as per the manufacturer’s instructions, with
100–300 ng of total RNA hybridized with probes at 65 °C
for 16–18 h before being placed into the automated
nCounter Prep in which samples were affixed to car-
tridges. Cartridges were then immediately placed into the
nCounter Digital Analyzer optical scanner and read at a
goal resolution of 550 fields of view, which is the max-
imum resolution for this instrument. Analysis was per-
formed using the nSolver 2.6 analysis software with
immune cell types based upon classifications by Newman
et al. and Bindea et al. [48, 49]. Probes used to classify cell
types were as follows; T cells (CD2, CD3e, CD3g, CD6g),
regulatory T cells (Tregs) (FoxP3), macrophages (CD68,
CD163,CD84), Th1 cells (CD38, Ctla4, IFN-g, LTA, Stat4,
Tbx1), Th2 cells (Cxcr6, Birc5, Gata3 Pmch, Stat6), and
dendritic cells (CCl17, Cdl7, Ccl22, Cd1d2).
Statistical analysis
Statistical analysis was performed using Student’s t test
and expressed as median with SD, with the exception of
analysis for Kaplan–Meier survival curves which utilized
Mantel–Cox analysis. p < 0.05 was considered significant.
Results
Expression of PD-1 and PD-L1 in E0771 and EMT-6 BC
cells and tumors
In-vitro PD-L1 expression on E0771 and EMT-6 cells was
examined by flow cytometry. As shown in Fig. 1a, each
BC cell line had basal PD-L1 expression, with E0771 cells
having slighter higher levels. When cells were stimulated
with IFNγ, levels of PD-L1 increased substantially in each
cell line compared with untreated cells, with levels in
EMT-6 cells reaching higher expression levels than those
observed in E0771 cells. Tumors derived from implanted
E0771 and EMT-6 cells also had detectable expression of
PD-1 and PD-L1. As shown in Fig. 1b, PD-1 and PD-L1
were detectable in both E0771 and EMT-6 tumor samples
by immunohistochemistry, thus supporting the evaluation
of combination therapy by antibodies targeting PS and the
PD-1/PD-L1 axis in these murine models.
Effect of PS targeting and PD-1 inhibition on in-vivo
growth in E0771 and EMT-6 cells
To determine the therapeutic effect of PS and PD-1 tar-
geting alone and in combination, mice were implanted
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orthotopically with cells from the murine TNBC line
E0771. When tumors reached approximately 100 mm3
(day 10), treatments commenced with twice-weekly
dosing for a total of six doses (3 weeks) by intraperi-
toneal injection. Treatment by the PS-targeting antibody,
mch1N11 (10 mpk), resulted in 55 % TGI compared with
control treatment (C44) (Fig. 2a, upper panel). Treatment
by anti-PD-1 antibody (2.5 mpk) resulted in a TGI of 71 %
compared with control treatment. Combinational treat-
ment of mch1N11 (10 mpk) with anti-PD-1 (2.5 mpk)
antibody significantly suppressed E0771 growth by 90 %
compared with control (Fig. 2a, upper panel). Comparison
of the final tumor volumes in each treatment group dem-
onstrated that, in addition to significantly suppressing the
growth of E0771 compared with control treatment (p <
0.0001), combination treatment by mch1N11and anti-PD-
1 significantly inhibited tumor growth more than treat-
ment by either single arm alone (Fig. 2a, lower panel, p =
0.0339 to anti-PD-1 treatment). In the EMT-6 BC model,
unlike the results observed in the E0771 model, mch1N11
(10 mpk) and the anti-PD-1 blocking antibody (2.5 mpk)
had no growth inhibitory effects as single agents (Fig. 2b,
upper panel). However, similar to the results from com-
bination treatment in the E0771 model, combining PS-
targeting and anti-PD-1 therapies together was capable of
significantly impeding tumor growth in the EMT-6 model
(TGI = 57 %, p = 0.005 to control treatment, Fig. 2b upper
and lower panels). No loss of weight was noted in any of
the treatment groups in the E0771 or EMT-6 models (data
not shown).
Effect of anti-PD1 and PS-targeting antibodies on overall
survival in a murine BC model
To determine whether treatment by mch1N11 and anti-
PD-1 therapy prolonged overall survival in a BC model,
mice inoculated with E0771 tumors were treated with
control antibody (C44, 10 mpk), mch1N11 (10 mpk), anti-
PD-1 antibody (10 mpk), or the combination of mch1N11
plus anti-PD-1 antibody (10 mpk/10 mpk). As shown in
Fig. 3 and summarized in Table 1, all control mice had tu-
mors that progressed with treatment by the C44 isotype
antibody and survived until day 25 of treatment, when the
end point was reached due to excessive tumor burden. All
mice receiving mch1N11 antibody also progressed while
receiving treatment, but were able to survive for an
additional 7 days beyond control mice. Mice receiving
anti-PD-1 therapy alone at 10 mpk survived significantly
longer than those receiving control or mch1N11 treat-
ments, having a median survival time of 55 days. Mice re-
ceiving the combination of mch1N11 with anti-PD-1
antibody experienced a significant increase (p = 0.0155) in
overall survival compared with single anti-PD-1 treatment,
with six of 10 mice having complete tumor regression by
day 25, compared with two of 10 mice in the anti-PD-1
A
B
Fig. 1 Expression of PD-L1 and PD-1 in breast tumors. FACS and immunohistochemistry (IHC) analysis of a E0771 and b EMT-6 cells grown in vitro to
determine whether PD-L1 is constitutively expressed and/or is inducible by IFNγ treatment. PD-1, programmed death 1, PD-L1 programmed death-1
ligand 1
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group, accompanied by no tumor reoccurrence 30 days
after the study end (day 60) in all animals with complete
regression (Table 1).
Effect of PD-1 and PS treatments on developing and
maintaining a durable anti-tumor response to secondary
tumor challenge by TNBC cells
To elucidate whether mice that had complete tumor re-
gression in the mch1N11 plus anti-PD-1 treatment
group (Fig. 3 and Table 1) were resistant to E0771 re-
challenge, the six mice that experienced complete tumor
regression and six control naïve mice were inoculated
with E0771 cells in the 4/5 mammary fat pad and tumor
growth was measured. After 10 days, the naïve mice had
an average tumor volume of 134 ± 5.3 mm3 compared
with 32.8 ± 4.6 mm3 in the E0771 rechallenged group
(Fig. 4a). On day 17, only three of the six mice in the
rechallenged group had detectable tumors with an aver-
age volume of 20.8 ± 10.5 mm3, compared with 199.8 ±
39.5 mm3 in control mice. On day 26 all mice in the
control group reached maximum study tumor volume
limits (1656 ± 210 mm3) while the tumors continued to
E0771
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Fig. 2 Anti-tumor effects of PS and PD-1 targeting alone and in combination in murine BC models. a Top panel: growth kinetics of E0771 TNBC
tumors in C57/Bl6 mice treated with control (C44 ), mch1N11, anti-PD-1, or mch1N11 + anti-PD-1 antibody combinations. Treatments started at
10 days post inoculation when tumors were approximately 100 mm3. All data points are expressed as median and SD. Bottom panel: analysis of
E0771 final tumor volumes from the TGI study in upper panel. Statistical analysis (Student’s t test) demonstrates that combinational treatment with
PS-targeting antibody and ant-PD-1 antibody has significant inhibitory effects compared with all other treatments. b Top panel: growth kinetics of
EMT-6 murine breast tumors in Balb/c mice treated with control (C44), mch1N11, anti-PD-1, or mch1N11 + anti-PD-1 antibody combinations.
Treatments started at 3 days post inoculation when tumors were approximately 100 mm3. All data points are expressed as median and SD. Bot-
tom panel: analysis of EMT-6 final tumor volumes from TGI study in upper panel. Statistical analysis demonstrates that combinational treatment with
PS-targeting antibody and anti-PD-1 antibody has significant inhibitory effects compared with all other treatments. Statistically significant differences
between groups were identified by Student’s t test, with 10 animals in each group. TGI tumor growth inhibition
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regress in the rechallenged group, with only two mice
having detectable tumors (average 9.2 ± 8.2 mm3). By
day 35 no tumors were detected in the rechallenge
group (Fig. 4a), and no tumor growth was noted for an
additional 14 days (data not shown).
Effect of PS-targeting and anti-PD-1 antibody treatment
on splenocyte IFNγ production
To ascertain whether the mice that experienced com-
plete tumor regression with mch1N11 and anti-PD-1
treatment and were subsequently resistant to E0771 re-
challenge (Fig. 4a) had an enhanced tumor-specific im-
mune response, we evaluated IFNγ production in
splenocytes cultured with and without irradiated E0771
cells by EliSpot (Fig. 4b). Splenocytes from nontumor-
bearing control animals (no treatment and C44 treated)
had similar IFNγ production when cultured in media
alone (naïve, 0.40 ± 0.23; naïve + C44 treated, 0.27 ±
0.27). When cultured in the presence of irradiated
E0771, there was a slight increase in IFNγ production in
naïve mice treated with the C44 control antibody com-
pared with nontreated mice (naïve, 0.13 ± 0.13; naïve +
C44 treated, 2.0 ± 0.46). In nontumor-bearing mice that
received mch1N11 and anti-PD-1 treatment, there was a
slight increase in IFNγ production when cultured in
media alone (9.0 ± 0.81); however, this signal did not in-
crease when irradiated E0771 cells were cocultured with
splenocytes from combination-treated animals (10.9 ±
1.71). Splenocytes from tumor-bearing mice that re-
ceived C44 control antibody had a signal of 10.7 ± 1.7
when grown in media alone, and IFNγ production in-
creased to 60.1 ± 4.8 spots per well with coculturing with
irradiated E0771 cells. In the animals with regressed tu-
mors following mch1N11 and anti-PD-1 treatment, and
further resistance to E0771 rechallenge (Fig. 4a, b), IFNγ
EliSpots were significantly higher than observed under
previous treatments and conditions. Splenocytes from
these animals cultured in media alone had a baseline
 E0771: Kaplan–Meier Analysis





























* Log-rank (Mantel-Cox) test
Fig. 3 Effect of PS-targeting and anti-PD-1 antibody therapy on survival in a TNBC murine model. Mice with E0771 tumors were treated a total of
six times once tumors reached approximately 100 mm3 (days 1, 4, 8, 11, 15, and 18) with single antibody or a combination of mch1N11 and anti-
PD-1, and survival times were determined. Once tumors reached approximately 1500 mm3 or animals encountered a tumor-related health problem,
animals were euthanized. Survival times were plotted and determined by Kaplan–Meier analysis, statistical analysis was determined by log rank
(Mantel–Cox) analysis
Table 1 Summary of Kaplan–Meier survival analysis of the E0771 in-vivo study (Fig. 3)
Median survival
Control (c44) mch1N11 aPD-1 mch1N11 + aPD-1
Days 25 32 55 Undefined
Hazard ratio – 0.1915 0.089 0.04557
CI of HR at 95 % – 0.003086–0.03911 0.0001420–0.004134 3.222 × 10–5–0.001361
Mice with complete regression 0 0 2 6
Data include median survival (days), hazard ratio (HR) confidence interval (CI) at 95 % of HR, and number of animals with each treatment that experienced
complete tumor regression
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signal of 347 ± 7.9 spots per well, suggesting mch1N11
and anti-PD-1 treatment increases the number of func-
tional T cells in the spleens of combination-treated ani-
mals, perhaps leading to the observed tumor regression
and subsequent rejection of tumor recolonization with
E0771 reinoculation. The addition of irradiated E0771
cells to these splenocytes elevated the signal to 614.7 ±
9.7 spots per well, demonstrating that E0771 antigens
are capable of further stimulating IFNγ production in
T cells from mch1N11 and anti-PD-1-treated animals
(Fig. 4b).
Effect of PS-targeting and anti-PD-1 antibodies on
TNBC TILs
The anti-tumor response induced by mch1N11 in
combination with anti-PD-1 in mice bearing the TNBC
model E0771 tumors suggests that treatment by PS and
PD-1-targeting antibodies may induce TIL changes within
the tumor microenvironment. Examination of excised
E0771 tumors at the study end in Fig. 2a demonstrated
that treatment by mch1N11 increased the presence of
CD45+ cells from a median value of 11.6 % in control
(C44) tumors to 18 % (p = 0.0179 to control) with PS
targeting, while anti-PD-1 therapy increased CD45+ levels
to 21 % (Fig. 5a). In combination treated mice, the
addition of mch1N11 to anti-PD-1 therapy significantly
increased CD45+ levels to 25.7 % (p < 0.0001 to C44
control, p = 0.0139 to anti-PD-1 single treatment). Exam-
ination of CD8+ and CD3+ levels (CD8+, CD3+, and CD4+
cells were all subpopulations of CD45+ cells) showed a
similar trend in response to treatments. Single mch1N11
treatments increased CD8+/CD3+ levels to 8.9 %/7.7 %
respectively over control levels (CD8+ = 5.7 %, CD3+ =
2.7 %). Single anti-PD-1 therapy increased CD8+ and CD3+
levels to 14.6 % and 11 % respectively, while the combin-
ation of PS with anti-PD-1 therapy elevated CD8+ levels
to 15.2 % and CD3+ levels to 12.8 %. Examination of the
CD4+ to CD8+ T-cell ratio demonstrated that while each
single arm treatment group decreased the percentage of
CD4+ to CD8+ cells, combinational therapy further signifi-
cantly decreased this ratio (p = 0.023), suggesting com-
bined treatment was capable of further reducing the CD4
T-cell helper populations and increasing the effector
CD8+ cells in the tumor microenvironment (Fig. 5a).
FACS examination of the EMT-6 in-vivo study (Fig. 2b)
demonstrated that, unlike our observations in the E0771
model, single-arm treatments had little observable effect
on altering TILs (Fig. 5b). C44 control CD45+ levels had a
median value of 36.8 %, while mch1N11 had a value of
34.7 % and anti-PD-1 of 33.4 %. Only in the combination
group was an increase in CD45+ noted (46.0 %, p =0.023).
In CD8+ populations, C44 control tumors were 12.0 %,
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Media + Irradiated E0771
E0771: EliSpot AnalysisA B
Fig. 4 Effect of mch1N11 and anti-PD-1 therapy on establishing an immune-mediated resistance to E0771 rechallenge and presence of functional
T cells. a Animals that received mch1N11 + anti-PD-1 treatment and underwent a complete tumor regression (Fig. 4) were rechallenged, along
with naïve C57BL/6 mice, with E0771 cells (1.0 × 106). Cells were inoculated in the opposing mammary fat pad (4/5) from the previous initial inocula-
tion (8/9). The presence of palpable tumors and growth kinetics was determined for each group. b EliSpot analysis of IFNγ in splenocytes cultured with
and without irradiated E0771 cells. Splenocytes from nontumor-bearing control animals (no treatment, C44, and mch1N11 + anti-PD-1 treated), tumor-
bearing animals (C44 treated), and mice resistance to E0771 rechallenge (Fig. 4a, 4b) were utilized. All analyses were performed in triplicate
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with mch1N11 of 11.80 % and anti-PD-1 exhibiting 7.6 %.
The combination treatment group did increase to 20.9 %,
but the results were not significant (p = 0.112). Similar re-
sults occurred in CD3+ populations. C44 control con-
tained 3.9 % CD3+ cells, while mch1N11 showed 2.6 %
and anti-PD-1 treatment showed 2.3 %. Again only the
combinational treatment arm showed a significant in-
crease to 18.4 % (p = 0.012, Fig. 5b). Examination of the
ratio of CD4+ to CD8+ T cells in EMT-6 tumors demon-
strated that all of the treatment arms slightly increased the
percentage of CD4 cells to CD8 cells; however, none of
the changes were statistically significant for control treat-
ment (C44 control, 0.9 %; mch1N11, 2.3 %; anti-PD-1
3.2 %; and mch1N11 + anti-PD1, 2.1 %).
Combined, our results in the E0771 model demon-
strate that while each single arm treatment is capable of
increasing CD45+, CD8+, and CD3+ populations in
E0771 tumors, combining PS-targeting and anti-PD-1
antibodies increases the percentage of TILs over that
observed with single treatments. Contrary to these re-
sults, only the combination of the PS blocking antibody
treatment with anti-PD-1 treatment in the EMT-6 model
was capable of inducing TILs, reflecting the TGI data in
Fig. 2a, b.
Effect of PS-targeting and anti-PD-1 therapy on RNA
immunoprofile in TNBC tumors
To further capture and understand changes in the im-
mune landscape that accompany PS-targeting and anti-
PD-1 therapies, RNA isolated from tumors obtained at
the study termination (shown in Fig. 2a) were subjected
to mRNA expression analysis utilizing NanoString™
PanCancer Immune Profiling Panel analysis based on clas-
sifications described by Newman et al. and Bindea et al.
[48, 49]. Differences in the expression patterns of genes
associated with CD45+, T cells (probes; CD2, CD3e, CD3g,
CD6g), and tumor-associated macrophages (probes; CD68,
CD163, CD84) showed that while single treatments were
capable of increasing the levels of these cell types, most
notable for CD45+ and T cells, over control (C44) levels,
combination treatment further enhanced levels of these
cell types compared with each single treatment (Fig. 6a).
Increased Treg (probe; Foxp3) levels occurred in all treat-
ment groups compared with the control, with anti-PD-1
therapy having slightly less overall levels compared with
treatments that included a PS-blocking antibody. Examin-
ation of Th1 (probes; CD38, Ctla4, IFN-g, LTA, Stat4,
Tbx1) and Th2 (probes; Cxcr6, Birc5, Gata3 Pmch, Stat6)
immunoprofiles showed that distinct changes occurred
Fig. 5 Effect of PS-targeting and anti-PD-1 therapies on TILs in E0771 and EMT-6 tumors. a Mice with E0771 tumors were treated on days 10, 14,
17, 21, and 25 post implantation with single antibody treatments or a combination of mch1N11 and anti-PD-1. Five tumors from each treatment
group were excised on day 26 and single-cell preparations were stained with antibodies specific to CD45+, CD8+, CD4+, and CD3+. Data are
expressed as the group median and percentages of an individual animal positive for a specific surface marker by FACS analysis. CD8+, CD3+, and
CD4+ cells were all subpopulations of CD45+ cells. b Mice with EMT-6 tumors were treated on days 10, 14, 17, 21, and 25 post implantation with
single antibody treatments or a combination of mch1N11 and anti-PD-1. Five tumors from each treatment group were excised on day 26 and
single-cell preparations were stained with antibodies specific to CD45+, CD8+, CD4+, and CD3+. Data are expressed as the group median and
percentages of individual animal positive for a specific for a surface marker by FACS analysis. CD8+, CD3+, and CD4+ cells were all subpopulations
of CD45+ cells

























































12 p = 0.014
p = 0.313








































































































































































































































































































Immune activating / tumor repression
Immune suppression / tumor promoting
B
C
C44 Control mch1N11 anti-PD-1 mch1N11+anti-PD-1
Fig. 6 NanoString immune-profiling analysis of tumor samples from control (C44), PS (mch1N11), and anti-PD-1 therapy. RNA isolated from tumors
obtained at the study termination (shown in Fig. 3) was subjected to analysis utilizing the NanoString™ nCounter PanCancer Immune Profiling Panel.
Expression values, expressed in log2 are graphically represented. a Profiling of tumor-associated immune cell type markers, including the markers
for PD-1 and its ligand PD-L1. b Expression profiling of immune-activating-associated cytokines in each treatment group. c Expression profiling of
immune-suppression-associated cytokines in each treatment group. DC dendritic cell, PD-1 programmed death 1, PD-L1 programmed death-1 ligand
1, Th T-helper, Treg regulatory T cell
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with each type of treatment. Th1 levels were increased
only when PD-1 therapy was included, either as a single
treatment or in combination with PS-blocking antibodies,
while Th2 levels increased over control levels with each
single treatment, and combination therapy brought Th2
levels down to those observed in control treatment mice
(Fig. 6a). Examination of dendritic cell markers (probes;
CCl17, Cdl7, Ccl22, Cd1d2) demonstrated that PS treat-
ment did not increase levels over control, while anti-PD-1
alone and when combined with mch1N11 both increased
levels similarly, suggesting that anti-PD-1 treatment in-
creased dendritic cell levels. Finally we examined levels of
PD-L1 and PD-1. Both single-arm treatments similarly in-
creased PD-L1 levels; however, combination treatment in-
creased PD-L1 mRNA levels over that observed in each
single arm (Fig. 6a). PD-1 levels increased slightly with
mch1N11 compared with control, while treatment with
anti-PD-1 alone or in combination similarly induced PD-1
mRNA levels in E0771 tumors. These data suggest that
combinational treatment with PS-targeting and anti-PD-1
antibodies increase immune cell infiltration (CD45, T cells,
macrophages) over each single-arm treatment and that
treatment with PS and anti-PD-1 is capable of inducing
PD-L1 levels which may further serve as available targets
for intervention with anti-PD-L1/PD-1 therapeutics.
Effect of PS-targeting and anti-PD-1 antibody therapy on
expression of pro-oncogenic and anti-oncogenic
associated cytokines in the TNBC
Numerous secreted cytokines and immunomodulatory
proteins are expressed in the tumor microenvironment
that are associated with immune system activation or sup-
pression [50, 51]. We examined the levels of cytokine
IFNγ, IL-10, and TNF mRNA in tumors following treat-
ments with single or a combination of mch1N11 and anti-
PD-1 antibody. IFNγ levels did not change with mch1N11;
however, anti-PD-1 single treatment and mch1N11 and
anti-PD-1 antibody combination increased IFNγ levels,
with the anti-PD-1-alone group having the highest levels
(Fig. 6b). Levels of IL-12 and TNF increased compared
with control in both single-arm treatment groups, with
combination treatment further enhancing expression of
each of these immune promoting factors over that ob-
served in either single treatment arm (Fig. 6b). Further
examination of immunosuppression associated cytokines,
including IL-4, IL-9, IL-10, IL-13, IL-17, and TGFβ, re-
vealed the complex changes associated within each of our
treatment groups (Fig. 6c). Levels of IL-4 and IL-9 were
unchanged from control levels in the mch1N11 and com-
binational mch1N11 and anti-PD-1 treatment groups;
however, anti-PD-1 treatment alone dramatically induced
IL-4 and IL-9 levels (Fig. 6c). IL-10 levels were also un-
affected by mch1N11 as a single agent; however, anti-PD-
1 therapy alone increased levels the most, with the
addition of PS antibody to anti-PD-1 therapy reducing IL-
10 levels. Similar induction of the immunosuppressing/
tumor-promoting cytokines IL-17 and IL-13 was noted
with anti-PD-1 treatment, with combination treatment
reducing levels below those observed in C44 control
mice. The only immunosuppressive/pro-oncogenic cyto-
kine assayed that showed an increase in mice receiving
mch1N11 therapy over that observed in the anti-PD-1 sin-
gle treatment arm was TGFβ. While all treatments in-
creased TGFβ levels over those observed in control
tumors, the combination of PS-targeting and anti-PD-1
antibodies induced levels higher than observed in each
single treatment arm (Fig. 6c).
Discussion
TNBC represents one of the most malignant subtypes of
BC. Current treatment strategies for patients diagnosed
with TNBC rely on systemic cytotoxic chemotherapeu-
tics, causing exposure of PS in the tumor microenviron-
ment, which in turn promotes an immunosuppressive
condition [14, 52]. Previous work has demonstrated that
PS-driven immune suppression can be blocked or re-
versed by PS-targeting antibodies [14, 22]. In this study,
we sought to ascertain whether inhibition of PS-mediated
immune suppression is capable of enhancing, or acting
synergistically, when combined with an inhibitory treat-
ment targeting the downstream checkpoint regulator PD-
1 in murine BC models, including TNBC. Here we
demonstrate that PS-targeting antibodies combined with
anti-PD-1 therapy have significantly greater anti-TGI than
either treatment alone (Fig. 3a, b). In the TNBC E0771
model, each single therapy had moderate activity (mch1N11,
TGI = 55 %; anti-PD-1, TGI = 71 %), but combination
treatment was capable of achieving significant TGI over
either single therapy (TGI = 90 %, p = 0.00339 compared
with anti-PD-1). Interestingly, in the EMT-6 breast model,
single treatments by PS-targeting or anti-PD-1 antibodies
had no discernible anti-tumorigenic effect and did not
modulate TILs. However, combining PS therapy with anti-
PD-1 therapy in the EMT-6 model showed activity and
achieved a TGI of 57 % and significantly increased CD45+
and CD3+ levels. While it is unclear why single-arm treat-
ments did not increase TILs, the higher baseline of CD45+
cells in the EMT-6 model (46.0 %) compared with the
E0771 model (11.6 %) may suggest a higher percentage of
myloid derived supressor cells (MDSC) or Tregs in the
EMT-6 tumor microenvironment that single-arm treat-
ments are unable to overcome. Regardless, our data in the
EMT-6 model suggest that combining PS-targeting anti-
bodies with PD-1-targeting therapies in BCs may have ac-
tivity regardless of sensitivity to single treatments,
although this requires further validation and investigation
into the potential mechanism(s) that contribute to this
sensitivity.
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Similar to our studies examining the anti-tumor growth
effects of PS-targeting antibodies with and without anti-
PD-1 therapy, we also demonstrate that combinational
therapy provides a distinct advantage over single-arm
treatments in the TNBC E0771 model (Fig. 3). PS-
targeting antibodies alone provided an additional 7 days of
survival over that in the control (32 vs. 25 days), while
anti-PD-1 therapy increased the survival time to an average
of 55 days. Combination treatment of PS-targeting with
anti-PD-1 antibodies significantly extended the survival
time (p = 0.0155 to single anti-PD-1 treatment), with the
average survival time being undefined due to six of the 10
animals experiencing complete tumor regression compared
with two of 10 animals in the anti-PD-1 group (Fig. 3).
In addition to demonstrating that combination treat-
ment inhibits tumor growth and extends overall survival,
we also show that PS-targeting antibodies and anti-PD-1
treatment is capable of activating immune system recog-
nition and elimination of secondary tumor challenge by
TNBC cells. In the animals that experienced complete
tumor regression with combinational treatment, tumor
cell reinoculation in the adjacent mammary fat pad
failed to establish any tumors and tumor cells were rap-
idly eliminated compared with naïve animals inoculated
simultaneously with an equal number of E0771 cells
(Fig. 4a). Animals that experienced the ability to reject
secondary challenge also showed elevated IFNγ produc-
tion in their splenocytes compared with naïve animals
treated with either control or PS-targeting and anti-PD-
1 therapy, which was further elevated by stimulation
with irradiated E0771 cells (Fig. 4b). Furthermore, while
tumor-bearing animals treated with control antibody did
have elevated IFNγ levels compared with nontumor-
bearing animals, the levels of IFNγ were 20-fold lower
than levels observed in animals that had tumor re-
gressions following combination treatment (Fig. 4b).
IFNγ has multiple immunoregulatory effects on a
variety of cell types, including the capacity to pro-
mote the activation of cytotoxic T lymphocytes, nat-
ural killer cells, and macrophages, in addition to
inducing and enhancing expression of class II MHC
antigens [53, 54]. Studies demonstrate that while IFNγ is
essential for the development and ability of T cells to
mount a specific anti-tumor response, it is also essential
for the ability of T cells generated in lymphoid organs, in-
cluding the spleen, to migrate to tumor sites and mount
an anti-tumor response [55, 56].
The importance and prognostic value of TILs in BC is
controversial [57]. BC has been generally considered a
cancer not amenable to immunotherapeutic interven-
tions. However, emerging studies have suggested that in
TNBC patients the presence of TILs may be an indicator
of higher response rates to neoadjuvant chemotherapy
and reduced distant reoccurrence, and may predict
better overall survival [58–60]. Our studies demon-
strate that combining PS-targeting antibody and anti-
PD-1 therapies increases levels of TILs more than ob-
served by either treatment as a single agent, and this
increase correlates with greater anti-tumor growth ef-
fects and better overall survival. Examination of che-
mokines in the E0771 model associated with
enhancing TILs (including Ccl3 and Ccl4) showed a
general trend of increased expression in the combin-
ation groups over each single arm; however, the re-
sults were not statistically significant (data not
shown). We also observed increased levels of tumor-
associated macrophages with combination treatment
by NanoString analysis. While we were are unable to
distinguish whether a M1/M2 repolarization event oc-
curred in the macrophage population with the murine
NanoString analysis, the increase in TNF and IL-12
accompanied by a decrease in IL-10 levels suggest
that a more M1-like phenotype may occur with com-
binational therapy. A shift to a M1 phenotype using a
PS blocking antibody has been reported previously [22],
but the prognostic value of the increase in the overall per-
centage of macrophages remains unknown [61–63].
Continued examination of our tumor immunoprofil-
ing of soluble factors demonstrates that with the ex-
ception of IFNγ, which was highest in the anti-PD-1
treatment group, combination treatment increased
levels of the immune-surveillance maturation and
promoting cytokines IL-12 and TNF over all other
treatment groups, suggesting that while PD-1 treat-
ment is capable of inducing these anti-tumor factors,
including PS-targeting antibodies with anti-PD-1
treatment is capable of further stimulating their pro-
duction. In addition, we observed elevated cytokine
expression levels of IL-4, IL-9, IL-10, IL-13, and IL-17
in the single anti-PD-1 treatment group, which were re-
duced in tumors from animals treated with PS-targeting
and anti-PD-1 treatments to levels equal to or less than
observed in the control group (Fig. 6c). These cytokines
are linked to both immunosuppressive and tumor-
promoting conditions in BCs. IL-4 is associated with en-
hanced metabolic pathways in BC, thereby promoting
tumor cell growth and metastatic disease [45]. IL-9
impedes adaptive immunity responses and the maturation
of T cells, while IL-10 can assist in tumor immune
surveillance escape [46, 64]. IL-13 and IL-17 expres-
sion are associated with the promotion of metastatic
disease in BCs, including those that are negative for
estrogen receptor expression [65, 66]. This suggests
that PS-targeting antibodies may further enhance the
pro-inflammatory/anti-tumor cytokine profile in the
tumor microenvironment by decreasing immuno-
suppressive/pro-tumorigenic cytokine expression in-
duced by anti-PD-1 therapy.
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Conclusions
In summary, our observations demonstrate that including
PS-targeting antibodies such as bavituximab can enhance
the anti-tumor activity of anti-PD-1/PD-L1 treatments,
not only by increasing TIL responses but also by inhibiting
cytokines stimulated by single-agent anti-PD-1 therapy
that serve to suppress the immune response and promote
tumor progression.
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